Patents by Inventor Dhanalakshmi Sivanandhan
Dhanalakshmi Sivanandhan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230027026Abstract: The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.Type: ApplicationFiled: September 26, 2020Publication date: January 26, 2023Inventors: Chandregowda Venkateshappa, Dhanalakshmi Sivanandhan, Sridharan Rajagopal, Bruce Roth, Anjali Pandey, Tracy Saxton, Gurulingappa Hallur, Naveena Madhyastha, Naveen Sadhu M
-
Patent number: 11529341Abstract: The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.Type: GrantFiled: March 13, 2019Date of Patent: December 20, 2022Inventors: Chandregowda Venkateshappa, Jeyaraj D A, Muralidhar Pendyala, Dhanalakshmi Sivanandhan, Sridharan Rajagopal
-
Patent number: 11459338Abstract: The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.Type: GrantFiled: November 23, 2018Date of Patent: October 4, 2022Assignee: JUBILANT EPISCRIBE LLCInventors: Saravanan Vadivelu, Sridharan Rajagopal, Raghunadha Reddy Burri, Shivani Garapaty, Dhanalakshmi Sivanandhan, Manish Kumar Thakur, Tamizharasan Natarajan, Indu N Swamy, Nagendra Nagaraju, Subramaniam Kanagaraj, Zainuddin Mohd, Sayantani Sarkar, Swapan Kumar Samanta, Hariprakash
-
Publication number: 20220281815Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.Type: ApplicationFiled: April 29, 2022Publication date: September 8, 2022Inventors: Sridharan RAJAGOPAL, Mahanandeesha S. HALLUR, Purushottam DEWANG, Kannan MURUGAN, Durga Prasanna KUMAR C.H., Pravin IYER, Chandrika MULAKALA, Dhanalakshmi SIVANANDHAN, Sreekala NAIR, Mohd ZAINUDDIN, Subramanyam Janardhan TANTRY, Chandru GAJENDRAN, Sriram RAJAGOPAL
-
Patent number: 11352322Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.Type: GrantFiled: May 8, 2017Date of Patent: June 7, 2022Assignee: Jubilant Epicore LLCInventors: Sridharan Rajagopal, Mahanandeesha S. Hallur, Purushottam Dewang, Kannan Murugan, Durga Prasanna Kumar C. H., Pravin Iyer, Chandrika Mulakala, Dhanalakshmi Sivanandhan, Sreekala Nair, Mohd Zainuddin, Subramanyam Janardhan Tantry, Chandru Gajendran, Sriram Rajagopal
-
Patent number: 11319326Abstract: The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.Type: GrantFiled: May 7, 2020Date of Patent: May 3, 2022Assignee: JUBILANT BIOSYS LIMITEDInventors: Saravanan Vadivelu, Sridharan Rajagopal, Murugan Chinnapattu, Pavan Kumar Gondrala, Dhanalakshmi Sivanandhan, Chandrika Mulakala
-
Patent number: 11267820Abstract: The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention, or suppression of diseases, an conditions mediated b one or more BET family of bromodomains.Type: GrantFiled: May 11, 2020Date of Patent: March 8, 2022Assignee: Jubilant Biosys LimitedInventors: Saravanan Vadivelu, Sridharan Rajagopal, Manjunatha M. Ramaiah, Pavan Kumar Gondrala, Murugan Chinnapattu, Dhanalakshmi Sivanandhan, Payal Kiran Parikh, Chandrika Mulakala
-
Publication number: 20220047569Abstract: Described herein is a method for treating and/or preventing a disease or disorder or condition associated with NETosis, the method comprising: administering to a subject a compound as disclosed herein, or its polymorph, stereoisomer, prodrug, solvate, co-crystal, intermediate, pharmaceutically acceptable salt, metabolite, or composition thereof. The compound or its polymorph, stereoisomer, prodrug, solvate, co-crystal, intermediate, pharmaceutically acceptable salt, metabolite, or composition thereof may be used in for treating and/or preventing a disease or disorder or condition associated with NETosis.Type: ApplicationFiled: August 12, 2021Publication date: February 17, 2022Inventors: Syed M I Kazmi, Sridharan Rajagopal, Dhanalakshmi Sivanandhan
-
Publication number: 20210371431Abstract: The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.Type: ApplicationFiled: November 23, 2018Publication date: December 2, 2021Inventors: Saravanan VADIVELU, Sridharan RAJAGOPAL, Raghunadha Reddy BURRI, Shivani GARAPATY, Dhanalakshmi SIVANANDHAN, Manish Kumar THAKUR, Tamizharasan NATARAJAN, Indu N SWAMY, Nagendra NAGARAJU, Subramaniam KANAGARAJ, Zainuddin MOHD, Sayantani SARKAR, Swapan Kumar SAMANTA, Hariprakash N/A
-
Publication number: 20210015810Abstract: The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.Type: ApplicationFiled: March 13, 2019Publication date: January 21, 2021Inventors: Chandregowda VENKATESHAPPA, Jeyaraj DA, Muralidhar PENDYALA, Dhanalakshmi SIVANANDHAN, Sridharan RAJAGOPAL
-
Publication number: 20200339595Abstract: The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention, or suppression of diseases, an conditions mediated b one or more BET family of bromodomains.Type: ApplicationFiled: May 11, 2020Publication date: October 29, 2020Applicant: JUBILANT BIOSYS LIMITEDInventors: Saravanan VADIVELU, Sridharan RAJAGOPAL, Manjunatha M. RAMAIAH, Pavan Kumar GONDRALA, Murugan CHINNAPATTU, Dhanalakshmi SIVANANDHAN, Payal Kiran PARIKH, Chandrika MULAKALA
-
Publication number: 20200331926Abstract: The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.Type: ApplicationFiled: May 7, 2020Publication date: October 22, 2020Applicant: JUBILANT BIOSYS LIMITEDInventors: Saravanan Vadivelu, Sridharan Rajagopal, Murugan Chinnapattu, Pavan Kumar Gondrala, Dhanalakshmi Sivanandhan, Chandrika Mulakala
-
Publication number: 20200308110Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.Type: ApplicationFiled: May 8, 2017Publication date: October 1, 2020Inventors: Sridharan RAJAGOPAL, Mahanandeesha S. HALLUR, Purushottam DEWANG, Kannan MURUGAN, Durga Prasanna KUMAR C.H., Pravin IYER, Chandrika MULAKALA, Dhanalakshmi SIVANANDHAN, Sreekala NAIR, Mohd ZAINUDDIN, Subramanyam Janardhan TANTRY, Chandru GAJENDRAN, Sriram RAJAGOPAL
-
Patent number: 10689395Abstract: The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.Type: GrantFiled: September 8, 2016Date of Patent: June 23, 2020Assignee: JUBILANT BIOSYS LIMITEDInventors: Saravanan Vadivelu, Sridharan Rajagopal, Manjunatha M. Ramaiah, Pavan Kumar Gondrala, Murugan Chinnapattu, Dhanalakshmi Sivanandhan, Payal Kiran Parikh, Chandrika Mulakala
-
Patent number: 10689390Abstract: The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.Type: GrantFiled: March 30, 2016Date of Patent: June 23, 2020Assignee: JUBILANT BIOSYS LIMITEDInventors: Saravanan Vadivelu, Sridharan Rajagopal, Murugan Chinnapattu, Pavan Kumar Gondrala, Dhanalakshmi Sivanandhan, Chandrika Mulakala
-
Patent number: 10273224Abstract: The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.Type: GrantFiled: July 10, 2014Date of Patent: April 30, 2019Assignee: Jubilant Biosys LimitedInventors: Chandregowda Venkateshappa, Dhanalakshmi Sivanandhan, Rajagopal Bakthavatchalam, Raghava Reddy Kethiri, Vellarkad Narayana Viswanadhan, Sanjeev Giri
-
Publication number: 20180282345Abstract: The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.Type: ApplicationFiled: March 30, 2016Publication date: October 4, 2018Applicant: JUBILANT BIOSYS LIMITEDInventors: Saravanan VADIVELU, Sridharan RAJAGOPAL, Murugan CHINNAPATTU, Pavan Kumar GONDRALA, Dhanalakshmi SIVANANDHAN, Chandrika MULAKALA
-
Publication number: 20180237453Abstract: The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.Type: ApplicationFiled: September 8, 2016Publication date: August 23, 2018Applicant: JUBILANT BIOSYS LIMITEDInventors: Saravanan VADIVELU, Sridharan RAJAGOPAL, Manjunatha M. RAMAIAH, Pavan Kumar GONDRALA, Murugan CHINNAPATTU, Dhanalakshmi SIVANANDHAN, Payal Kiran PARIKH, Chandrika MULAKALA
-
Publication number: 20160222014Abstract: The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: September 5, 2014Publication date: August 4, 2016Applicant: Asana Biosciences, LLCInventors: Aranapakam M. Venkatesan, Roger A. Smith, Scott K. Thompson, Nicholas Laping, Bheemashankar Kulkarni, Gurulingappa Hallur, Vellarkad N. Viswanadhan, Muralidhar Pendyala, Raghava Reddy Kethiri, Rajiv Tyagi, Dhanalakshmi Sivanandhan, Rajagopal Bakthavatchalam
-
Publication number: 20160207905Abstract: The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.Type: ApplicationFiled: July 10, 2014Publication date: July 21, 2016Inventors: CHANDREGOWDA VENKATESHAPPA, DHANALAKSHMI SIVANANDHAN, RAJAGOPAL BAKTHAVATCHALAM, RAGHAVA REDDY KETHIRI, VELLARKAD NARAYANA VISWANADHAN, SANJEEV GIRI